SIRT2

Across TCGA pan-cancer cohorts, SIRT2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SIRT2 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SIRT2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SIRT2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

HNSC, LUAD, and GBM are the cancer types where SIRT2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.678	0.864	.004	14	view →
LUAD	DFS	Tertile	All	1.000	0.504	.008	12	view →
GBM	OS	Quartile	All	0.186	0.572	.013	6	view →
CCRCC	DFS	Median	All	0.606	0.878	.002	5	view →
PDAC	DFS	Median	II,III,IV	0.495	0.324	.049	2	view →
LSCC	OS	Median	All	0.806	1.000	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SIRT2–HNSC (DFS)

Open the HNSC breakdown →